Notice of Approval | Oct 25, 2017 | PAPER | BOARD |
Petitioner's Request for Refund of IPR Fees | Oct 16, 2017 | PAPER | PETITIONER |
Joint Motion to Terminate Proceedings | Sep 20, 2017 | PAPER | PATENT OWNER |
Joint Request to Treat Agreement as Business Confidential | Sep 20, 2017 | PAPER | PATENT OWNER |
Ex 2001 Settlement Agreement | Sep 20, 2017 | EXHIBIT | PATENT OWNER |
Termination Decision Document | Sep 20, 2017 | PAPER | BOARD |
Power of Attorney | Mar 30, 2017 | PAPER | PATENT OWNER |
Mandatory Notice | Mar 30, 2017 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Mar 21, 2017 | PAPER | BOARD |
MYLAN EX. 1001 U.S. Patent No. 9,320,716 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1006 Declaration of Anthony Palmieri III, Ph.D., R.Ph. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1007 Curricula Vitae of Anthony Palmieri, Ph.D., R.Ph. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1009 U.S. Patent No. 5,811,388 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1002 U.S. Patent No. 8,784,888 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1008 U.S. Patent No. 5,681,584 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1010 U.S. Patent No. 6,239,120 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1011 U.S. Patent Appl. Pub. No. 2006/0134208 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1013 Amendment and Response to Advisory | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1014 Substitute Specification (Clean Copy) U.S. Patent Appl. No. 13/617,138 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1017 U.S. Patent No. 6,607,751 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1022 PCT International Publication No. WO 96/36318 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1028 Remington: The Science and Practice of Pharmacy, Vol. 1 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1030 Hawley¿¿¿s Condensed Chemical Dictionary | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1012 Markman Opinion and Order | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1015 Amendment After Final | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1016 Amendment and Response to Office Action | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1018 Campieri et al., | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1023 U.S. Patent No. 5,342,625 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1024 PCT International Publication No. WO 99/39700, | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1025 FDA Inactive Ingredient Guide 1996/1997 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1026 Handbook of Pharmaceutical Excipients | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1032 Entocort¿¿ EC Highlights of Prescribing Information | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1038 Daly et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1039 S.S. Davis, The Design and Evaluation of Controlled Release Dosage Forms for Oral Delivery | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1042 U.S. Provisional Application No. 60/080,274 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1044 See A Blume, B Arnold, HU Weltzien, | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1047 Uceris¿¿ website | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1048 Santarus¿¿¿ CEO Discusses FDA Approval Of UCERIS | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1033 Svensson et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1034 U.S. Patent No. 6,395,300 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1035 Flanders et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1036 Gandhi et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1037 US Patent No. 4,880,830 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1040 U.S. Patent No. 5,849,327 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1041 U.S. Patent No. 5,643,602 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1043 Gliko-Kabir et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1045 Qiu et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1046 M. Efentakis et al. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1050 Transcript of the Second Quarter 2014 Earnings Conference Call of Salix Pharmaceuticals, Ltd. | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1051 L.W. Doner | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1055 Specification of 13/249,839 application | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1056 Specification of 13/462,409 application | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1049 Uceris¿¿ Instant Savings Program | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1052 Amendment filed on January 15, 2013 in U.S. Patent Appl. No. 13/617,138 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1053 Specification of U.S. Patent Application No. 10/009,532 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1054 Specification of 12/210,969 application | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1061 Hawley¿¿¿s Condensed Chemical Dictionary | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1062 N. Robinson, Surface Interaction of Lecithin and Lysolecithin, J. of Pharmacy and Pharmacology | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1057 Final Office Action of March 6, 2013 in U.S. Patent Appl. No. 13/617,138 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1058 Applicant-Initiated Interview Summary of April 23, 2013 in U.S. Patent Appl. No. 13/617,138 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1059 Original Specification as field on September 14, 2012 in U.S. Patent Appl. No. 13/617,138 | Mar 9, 2017 | EXHIBIT | PETITIONER |
MYLAN EX. 1060 Orange Book Listing of Uceris | Mar 9, 2017 | EXHIBIT | PETITIONER |
Petition for Inter Partes Review | Mar 9, 2017 | PAPER | PETITIONER |
Petitioner's Power of Attorney | Mar 9, 2017 | PAPER | PETITIONER |
Petitioner's Exhibit List | Mar 9, 2017 | PAPER | PETITIONER |